Abstract
As chemists can easily produce large numbers of new potential drug candidates, there is growing demand for high capacity models that can help in driving the chemistry towards efficacious and safe candidates before progressing towards more complex models. Traditionally, the cardiovascular (CV) safety domain plays an important role in this process, as many preclinical CV biomarkers seem to have high prognostic value for the clinical outcome. Throughout the industry, traditional ion channel binding data are generated to drive the early selection process. Although this assay can generate data at high capacity, it has the disadvantage of producing high numbers of false negatives. Therefore, our company applies the isolated guinea pig right atrium (GPRA) assay early-on in discovery. This functional multi-channel/multi-receptor model seems much more predictive in identifying potential CV liabilities. Unfortunately however, its capacity is limited, and there is no room for full automation. We assessed the correlation between ion channel binding and the GPRA’s Rate of Contraction (RC), Contractile Force (CF), and effective refractory frequency (ERF) measures assay using over six thousand different data points. Furthermore, the existing experimental knowledge base was used to develop a set of in silico classification models attempting to mimic the GPRA inhibitory activity. The Naïve Bayesian classifier was used to built several models, using the ion channel binding data or in silico computed properties and structural fingerprints as descriptors. The models were validated on an independent and diverse test set of 200 reference compounds. Performances were assessed on the bases of their overall accuracy, sensitivity and specificity in detecting both active and inactive molecules. Our data show that all in silico models are highly predictive of actual GPRA data, at a level equivalent or superior to the ion channel binding assays. Furthermore, the models were interpreted in terms of the descriptors used to highlight the undesirable areas in the explored chemical space, specifically regions of low polarity, high lipophilicity and high molecular weight. In conclusion, we developed a predictive in silico model of a complex physiological assay based on a large and high quality set of experimental data. This model allows high throughput in silico safety screening based on chemical structure within a given chemical space.
Similar content being viewed by others
References
Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) Cell 81:299
Jackman WM, Clark M, Friday KJ, Aliot EM, Anderson J, Lazzara R (1984) Med Clin North Am 68:1079
Roden DM (2004) N Engl J Med 350:1013
Cavero I, Mestre M, Guillon JM, Crumb W (2000) Expert Opin Pharmacother 1:947
Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Cardiovasc Res 58:32
Miyahara JT, Akau CK, Yasumoto T (1979) Res Commun Chem Pathol Pharmacol 25:177
Palaoglu O, Soydan S, Bokesoy TA (1982) Pharmacology 25:183
Studenik C, Lemmens-Gruber R, Heistracher P (1999) Pharmazie 54:330
Kobayashi Y, Hoshikuma K, Nakano Y, Yokoo Y, Kamiya T (2001) Planta Med 67:244
Vasconcelos CM, Araujo MS, Silva BA, Conde-Garcia EA (2005) Braz J Med Biol Res 38:1113
Aronov AM (2006) J Med Chem 49:6917
Aronov AM, Goldman BB (2004) Bioorg Med Chem 12:2307
Dubus E, Ijjaali I, Petitet F, Michel A (2006) ChemMedChem 1:622
Farid R, Day T, Friesner RA, Pearlstein RA (2006) Bioorg Med Chem 14:3160
O’Brien SE, de Groot MJ (2005) J Med Chem 48:1287
Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D (2003) Bioorg Med Chem Lett 13:1829
Rajamani R, Tounge BA, Li J, Reynolds CH (2005) Bioorg Med Chem Lett 15:1737
Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G (2002) Chembiochem 3:455
Sanguinetti MC, Mitcheson JS (2005) Trends Pharmacol Sci 26:119
Pearlstein R, Vaz R, Rampe D (2003) J Med Chem 46:2017
Ekins S (2004) Drug Discov Today 9:276
Aronov AM (2005) Drug Discov Today 10:149
Rogers D, Brown RD, Hahn M (2005) J Biomol Screen 10:682
Ghose AK, Viswanadhan VN, Wendoloski JJ (1998) J Phys Chem A 102:3762
Csizmadia F, Tsantili-Kakoulidou A, Panderi I, Darvas F (1997) J Pharm Sci 86:865
Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001) J Chem Inf Comput Sci 41:1488
Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI (2006) Drug Discov Today 11:700
Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H (2000) Bioinformatics 16:412
Mehta CR, Patel NR, Tsiatis AA (1984) Biometrics 40:819
Barnard JM, Downs GM (1992) J Chem Inf Comput Sci 32:644
Engels MF, Thielemans T, Verbinnen D, Tollenaere JP, Verbeeck R (2000) J Chem Inf Comput Sci 40:241
Tetko IV, Sushko I, Pandey AK, Zhu H, Tropsha A, Papa E, Oberg T, Todeschini R, Fourches D, Varnek A (2008) J Chem Inf Model 48:1733
Hoffmann P, Warner B (2006) J Pharmacol Toxicol Methods 53:87
Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathofer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Naunyn Schmiedebergs Arch Pharmacol 368:404
Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC (2003) Mol Pharmacol 63:1051
Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) Proc Natl Acad Sci USA 97:12329
Buyck C, Tollenaere J, Engels M, De Clerck F (2002) Designing drugs and crop protectants: processes, problems and solutions. EuroQSAR 2002
Müller-Ehmsen J, Näbauer M, Schwinger RHG (1999) Naunyn Schmiedebergs Arch Pharmacol 359:60
Schiffmann H, Rizouli V, Luers F, Hackmann F, Hoebel D, Pfahlberg A, Hellige G (2003) Pediatr Res 54:875
Hoey A, Amos GJ, Wettwer E, Ravens U (1994) J Cardiovasc Pharmacol 23:907
Budriesi R, Cosimelli B, Ioan P, Lanza CZ, Spinelli D, Chiarini A (2002) J Med Chem 45:3475
Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M (2006) Mol Pharmacol 69:266
Wang L, Chiamvimonvat N, Duff HJ (1993) J Pharmacol Exp Ther 264:1056
Shirayama T, Inoue D, Inoue M, Tatsumi T, Yamahara Y, Asayama J, Katsume H, Nakagawa M (1991) J Pharmacol Exp Ther 259:884
Acknowledgments
This work was a collaborative effort of the ADME-Tox, Molecular Informatics, Enabling Technologies (HTS) departments and the Centre of Excellence for Cardiovascular Safety Research at J&J-PRD, Beerse. Our thanks go to all members of the departments involved and in particular to Danny Geyskens for the generation of the large high quality GPRA-assay dataset and Luc Gys for generation of the receptor binding data.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fenu, L.A., Teisman, A., De Buck, S.S. et al. Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay. J Comput Aided Mol Des 23, 883–895 (2009). https://doi.org/10.1007/s10822-009-9306-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-009-9306-z